BASED ON THE INFORMATION PROVIDED WE ARE UNABLE TO DETERMINE TO WHAT EXTENT IF ANY, THE BARD DEVICE MAY HAVE CAUSED OR CONTRIBUTED TO THE PATIENT POST OPERATIVE DIARRHEA. A PROBIOTIC REGIMEN WAS RECOMMENDED AS TREATMENT AND THE PATIENT CONDITION IS REPORTED TO BE RESOLVING. A REVIEW OF THE MANUFACTURING RECORDS WAS PERFORMED AND FOUND THAT THE LOT WAS MANUFACTURED TO SPECIFICATION. SHOULD ADDITIONAL INFORMATION BE REPORTED REGARDING THE PATIENT'S CONDITION, A SUPPLEMENTAL MDR WILL BE SUBMITTED. THE INFORMATION PROVIDED BY BARD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT / REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BARD. REMAINS IMPLANTED.
D
Patient 1
THE FOLLOWING WAS REPORTED AND IS ASSOCIATED WITH THE PHASIX STUDY DVL-HE-012. ON (B)(6) 2016 - THE PATIENT WAS IMPLANTED WITH A BARD XENMATRIX AB GRAFT. ON (B)(6) 2016 - THE PATIENT PRESENTED FOR FOLLOW UP VISIT. THE PATIENT REPORTS POST OPERATIVE DIARRHEA OCCURRING ROUGHLY 2-3 DAYS /WEEK. A PROBIOTIC REGIMEN WAS RECOMMENDED (AT LEAST 1OZ OF KEFIR/YOGURT FOR NEXT 2 MONTHS). OUTCOME IS REPORTED AS "RESOLVING" AND THE PATIENT STATES THAT SHE IS GETTING BETTER. THIS EVENT WAS ASSESSED AS POSSIBLY RELATED TO THE DEVICE.